IGN523

Igenica Biotherapeutics, Inc. · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	IGN523
Sponsor	Igenica Biotherapeutics, Inc.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

IGN523 CI brief — competitive landscape report
IGN523 updates RSS · CI watch RSS
Igenica Biotherapeutics, Inc. portfolio CI